Related Experiment Video
Updated: Jul 11, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Molecular targets in metastasis: lessons from genomic approaches
1Department of Cancer Biology, 771 PRB, Vanderbilt University Medical Center, Nashville, TN 37232-6840, USA. barbara.fingleton@Vanderbilt.edu
Abstract:
Microarray studies have yielded valuable information that can be used to determine a cancer patient's prognosis and allow for optimum treatment choices. Tumor profiling has also changed our perception of metastatic propensity. Genomic analyses clearly showed that a metastasis signature is encoded within the genome so that when a cancer develops, the likelihood of metastasis is high, whereas other cancers which do not have this genotype metastasize as a result of random mutations. It is certain however, that cells other than tumor cells contribute to the development of metastasis through their production of various pro-metastatic proteins. Here, we review the published metastasis profiling studies and the role of the host in metastasis. Collagen type I, CXCR4, CSF-1, OPN and RhoC are metastasis-associated genes for which evidence exists for a causal contribution to elements of the metastatic process. These genes are discussed in detail and represent excellent drug targets for anti-metastasis therapies.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets

